

**American College of Radiology
ACR Appropriateness Criteria®
Lower Urinary Tract Symptoms-Suspicion of Benign Prostatic Hyperplasia**

Variant 1: Lower urinary tract symptoms. Suspicion of benign prostatic hyperplasia. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
US pelvis (bladder and prostate) transabdominal	May Be Appropriate	○
US kidneys retroperitoneal	May Be Appropriate	○
MRI pelvis without IV contrast	Usually Not Appropriate	○
Radiography intravenous urography	Usually Not Appropriate	☼☼☼
Fluoroscopy voiding cystourethrography	Usually Not Appropriate	☼☼
MRI pelvis without and with IV contrast	Usually Not Appropriate	○
Radiography abdomen	Usually Not Appropriate	☼☼
TRUS prostate	Usually Not Appropriate	○
CT abdomen and pelvis with IV contrast	Usually Not Appropriate	☼☼☼
CT abdomen and pelvis without and with IV contrast	Usually Not Appropriate	☼☼☼☼
CT abdomen and pelvis without IV contrast	Usually Not Appropriate	☼☼☼
Fluoroscopy retrograde urethrography	Usually Not Appropriate	☼☼☼

LOWER URINARY TRACT SYMPTOMS-SUSPICION OF BENIGN PROSTATIC HYPERPLASIA

Expert Panel on Urological Imaging: Lauren F. Alexander, MD^a; Aytakin Oto, MD^b; Brian C. Allen, MD^c; Oguz Akin, MD^d; Jaron Chong, MD^e; Adam T. Froemming, MD^f; Pat F. Fulgham, MD^g; Stanley Goldfarb, MD^h; Jodi K. Maranchie, MDⁱ; Rekha N. Mody, MD^j; Bhavik N. Patel, MD, MBA^k; Nicola Schieda, MD^l; David M. Schuster, MD^m; Ismail B. Turkbey, MDⁿ; Aradhana M. Venkatesan, MD^o; Carolyn L. Wang, MD^p; Mark E. Lockhart, MD, MPH.^q

Summary of Literature Review

Introduction/Background

Lower urinary tract symptoms (LUTS) in men have multiple causes that can be broken down into storage, voiding, and postmicturition symptoms that are due to a wide range of neurogenic and non-neurogenic factors. These symptoms may be due to bladder outlet obstruction (BOO) caused by benign prostatic enlargement (BPE) or abnormal bladder detrusor function (overactivity or underactivity) [1]. BPE results from benign prostatic hyperplasia, a histologic diagnosis of benign proliferation of prostatic stromal and epithelial tissue [2]. BPE associated with LUTS has prevalence as high as 50% to 75% of men who are ≥ 50 years of age, and up to 80% of men who are >70 years of age [3].

Initial assessment of LUTS includes obtaining relevant medical history, performing a focused physical examination, and assessing symptom severity by one of several validated questionnaires. The International Prostate Symptom Score (IPSS) is used most commonly in the United States, and other validated questionnaires include the International Consultation on Incontinence Questionnaire and the Danish Prostate Symptom Score. These scores identify dominant symptoms (storage or voiding) and can be used to monitor response to therapy. Voiding charts (eg, frequency-volume chart) can be created by the patient to actively record several days of voiding time and volume. A physical examination should include an abdominal examination for bladder distention, a detailed genitourinary examination for any stricturing disease or urethral mass, a digital rectal examination to assess prostate size, and a neurological examination of the perineum and lower limbs. Digital rectal examination can be inaccurate for volume estimation and cancer detection and is most useful for identifying an enlarged prostate with volume >50 g [4]. Initial laboratory analysis may include prostate serum antigen level if desired, following appropriate shared decision-making discussion. Urinalysis can be obtained to evaluate for urinary tract infection, glucosuria and proteinuria as cause of urinary frequency, and microhematuria. Urinalysis results may lead to an additional workup beyond the scope of this topic [1,2,5]. Pressure flow urodynamics is considered the reference standard for determining the underlying cause of LUTS and differentiating between storage and voiding abnormalities.

Watchful waiting with lifestyle modifications is appropriate for patients without bothersome symptoms. For patients with moderate to severe symptoms, medical therapy with $\alpha 1$ -adrenoceptor antagonists is a first-line therapy. The 5α -reductase inhibitors can be helpful for patients with prostate volume >40 mL [6]. The muscarinic receptor antagonists and phosphodiesterase type 5 inhibitors can be used for storage symptoms [6]. Transurethral resection of the prostate is the standard surgical treatment for prostate volume 30 to 80 mL, with surgery or transurethral holmium laser enucleation for prostate volume >80 mL [6]. Other interventional options include laser ablation, transurethral needle or microwave ablation, transurethral resection, and prostate artery embolization. Treatment decisions vary by prostate volume and patient comorbidities [6,7].

^aMayo Clinic, Jacksonville, Florida. ^bPanel Chair, University of Chicago, Chicago, Illinois. ^cPanel Vice-Chair, Duke University Medical Center, Durham, North Carolina. ^dMemorial Sloan Kettering Cancer Center, New York, New York. ^eMcGill University, Montreal, Quebec, Canada. ^fMayo Clinic, Rochester, Minnesota. ^gUrology Clinics of North Texas, Dallas, Texas; American Urological Association. ^hUniversity of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; American Society of Nephrology. ⁱUPMC, Pittsburgh, Pennsylvania; American Urological Association. ^jCleveland Clinic, Cleveland, Ohio. ^kStanford University Medical Center, Stanford, California. ^lOttawa Hospital Research Institute and the Department of Radiology, The University of Ottawa, Ottawa, Ontario, Canada. ^mEmory University Hospital, Atlanta, Georgia. ⁿNational Institutes of Health, Bethesda, Maryland. ^oThe University of Texas MD Anderson Cancer Center, Houston, Texas. ^pUniversity of Washington, Seattle Cancer Care Alliance, Seattle, Washington. ^qSpecialty Chair, University of Alabama at Birmingham, Birmingham, Alabama.

The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document.

Reprint requests to: publications@acr.org

Discussion of Procedures by Variant

Variant 1: Lower urinary tract symptoms. Suspicion of benign prostatic hyperplasia. Initial imaging.

Radiography Abdomen

Radiographs do not directly image the prostate and are of low diagnostic yield in patients with LUTS [8]. A distended bladder may be visible on radiographs as a pelvic mass; however, the timing of last void is usually unavailable, making this appearance a finding of uncertain significance. Bladder stones can be identified on radiographs.

Radiography Intravenous Urography

Intravenous urography is now rarely performed as it has been replaced by CT urography at most centers [9]. Positive yield of intravenous urography for BOO is <15% [10,11]. In patients with stones, hematuria, or atypical history, CT urography may be considered for further evaluation [12].

Fluoroscopy Retrograde Urethrography

Retrograde urethrography does not directly image the prostate or provide adequate evaluation of prostate size. It may be useful if urethral stricture is considered as a cause of urinary obstruction.

Fluoroscopy Voiding Cystourethrography

Voiding cystourethrography does not directly image the prostate or provide adequate evaluation of prostate size. It may be useful if urethral stricture is considered as a cause of urinary obstruction.

TRUS Prostate

Grayscale transrectal ultrasound (TRUS) is the most commonly used modality to image the prostate. Although more invasive, TRUS measurement of prostate volume is more accurate than digital rectal examination or pelvic US [13,14], though correlation between TRUS and pelvic US is consistent when bladder volumes are <400 mL [15]. Prostate volume has low correlation with initial symptoms [16] but may predict symptom progression and response to 5 α -reductase inhibitors, as well as guide surgical procedures [6]. The addition of spectral Doppler assessment is not helpful to differentiate benign from malignant areas [17], and further study of prostate arterial resistive index measurement is needed to determine clinical usefulness [18].

US Pelvis

US is the preferred method to assess bladder volume and postvoid residual over catheterization and can be performed with a specific bladder scan unit or pelvic US. A measurable postvoid residual can be seen with both BOO and decreased detrusor function. Although no current postvoid residual threshold value can diagnose BOO or guide treatment [1,2], a persistent postvoid residual >100 mL or increasing postvoid residual over time may predict acute urinary retention, poor response to medical treatment, and deterioration of symptoms [1,19].

Pelvic US can assess intravesical prostatic protrusion, which is postulated to contribute to BOO by ball-valve mechanism disrupting flow of urine at the bladder neck [20,21]. Measurement of prostate protrusion into the bladder lumen from its tip to the bladder wall at the prostate base is broken down into 3 grades: grade I, \leq 5 mm; grade II, 6 to 10 mm; and grade III, >10 mm. A higher grade can predict BOO [21,22] and a likelihood of voiding trial failure after catheterization for acute urinary retention [23]. Intravesical prostatic protrusion is a better predictor than prostate volume of obstructive symptoms [19,24]. A study of 157 patients, of which 48 had BOO by urodynamics, identified by receiver operator curve analysis an optimal cutoff of 10.8 mm protrusion for identifying patients with BOO [25]. Accurate measurements require bladder volume between 100 and 200 mL as volumes >400 mL have inaccurate measurements and are possibly due to displacement of the prostate [15]. The intravesical prostatic protrusion measurement can also be performed during TRUS with similar results [26,27].

US measurement of bladder wall thickness includes the entire width of the bladder wall, whereas detrusor wall thickness measures the hypoechoic muscle between the more echogenic mucosa and adventitia. A study of 157 patients, of which 48 had BOO by urodynamics, identified optimal cutoff of 3.7-mm wall thickness for identifying patients with BOO by receiver operator curve analysis [25]. Although detrusor wall thickening has been shown to increase in BOO, the ratio of bladder to detrusor thickness depends on degree of bladder filling [28]. US-estimated bladder weight can be calculated from bladder volume and wall thickness, assuming a spherical shape. This value may also correlate with BOO and acute urinary retention [29,30].

US Kidneys Retroperitoneal

Routine imaging of the upper urinary tract with renal US is not usually indicated in uncomplicated LUTS [1,2,31]. In patients with elevated creatinine, stones, hematuria, urinary tract infection, or other complicating history, US of the kidneys and retroperitoneum may be considered for further evaluation.

CT Abdomen and Pelvis

There is little relevant literature on the use of CT in the initial evaluation of LUTS that are due to BPE, either with or without intravenous contrast. The prostate volume can be estimated with measurements in 3 planes and ellipsoid formula calculation and/or postprocessing software with high correlation with TRUS prostate volume measurements [32]. Prostate volume may be helpful to predict response to medical therapies and may help determine surgical technique [2]. CT has decreased soft-tissue contrast compared with US and MRI, limiting its assessment of zonal anatomy [31]. In patients with stones, hematuria, urinary tract infection, or other complicating history, CT urography may be considered for further evaluation.

MRI Pelvis

There is little relevant literature on the use of MRI in the initial evaluation of LUTS that are due to BPE. The role of MRI in evaluation for prostate cancer is discussed in the ACR Appropriateness Criteria® topic on “[Prostate Cancer-Pretreatment Detection, Surveillance, and Staging](#)” [33]. The high-contrast soft-tissue resolution on multiplanar T2 sequences allows for greatest delineation of zonal anatomy, which can be used to assess both total gland volume and zonal volume and can better evaluate the specific locations of enlargement and benign prostatic hyperplasia type to help guide treatment [34]. Prostate volume may be helpful to predict response to medical therapies and may help determine surgical technique [2]. Semiautomated volume analysis of 503 patients showed positive correlation of increased total and central gland volume with increasing age and serum prostate antigen level [35]. In 61 patients undergoing prostatectomy, there was correlation of measurements on preoperative MRI, including total prostate volume, transitional zone volume, and intravesical prostatic protrusion, with total IPSS. The transitional zone volume was the only predictor for total IPSS based on multiple regression analysis [36]. Detailed classification of the BPE pattern may be helpful for pre- and post-treatment assessment of patients undergoing prostatic artery embolization [37]. The differentiation of benign BPE changes from prostate adenocarcinoma in the transition zone remains challenging and an area of continued research; however, MRI has higher sensitivity for adenocarcinoma than other imaging modalities if malignancy is a consideration (see the separate ACR Appropriateness Criteria® topic on “[Prostate Cancer-Pretreatment Detection, Surveillance, and Staging](#)” [33]). It is also useful for guidance of tumor sampling on TRUS by implementing fusion of the MRI and real-time US imaging, beyond standard biopsy technique [38].

Summary of Recommendations

- **Variation 1:** US pelvis (bladder and prostate) transabdominal or US kidneys retroperitoneal may be appropriate for the initial imaging evaluation of lower urinary tract symptoms secondary to probable benign prostatic hyperplasia. These procedures are equivalent alternatives if the US kidneys retroperitoneal protocol includes bladder assessment (ie, only one procedure will be ordered to provide the clinical information to effectively manage the patient’s care).

Supporting Documents

The evidence table, literature search, and appendix for this topic are available at <https://acsearch.acr.org/list>. The appendix includes the strength of evidence assessment and the final rating round tabulations for each recommendation.

For additional information on the Appropriateness Criteria methodology and other supporting documents go to www.acr.org/ac.

Appropriateness Category Names and Definitions

Appropriateness Category Name	Appropriateness Rating	Appropriateness Category Definition
Usually Appropriate	7, 8, or 9	The imaging procedure or treatment is indicated in the specified clinical scenarios at a favorable risk-benefit ratio for patients.
May Be Appropriate	4, 5, or 6	The imaging procedure or treatment may be indicated in the specified clinical scenarios as an alternative to imaging procedures or treatments with a more favorable risk-benefit ratio, or the risk-benefit ratio for patients is equivocal.
May Be Appropriate (Disagreement)	5	The individual ratings are too dispersed from the panel median. The different label provides transparency regarding the panel's recommendation. "May be appropriate" is the rating category and a rating of 5 is assigned.
Usually Not Appropriate	1, 2, or 3	The imaging procedure or treatment is unlikely to be indicated in the specified clinical scenarios, or the risk-benefit ratio for patients is likely to be unfavorable.

Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, because of both organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared with those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria® [Radiation Dose Assessment Introduction](#) document [39].

Relative Radiation Level Designations		
Relative Radiation Level*	Adult Effective Dose Estimate Range	Pediatric Effective Dose Estimate Range
○	0 mSv	0 mSv
⊕	<0.1 mSv	<0.03 mSv
⊕⊕	0.1-1 mSv	0.03-0.3 mSv
⊕⊕⊕	1-10 mSv	0.3-3 mSv
⊕⊕⊕⊕	10-30 mSv	3-10 mSv
⊕⊕⊕⊕⊕	30-100 mSv	10-30 mSv

*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (eg, region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as "Varies."

References

1. Gratzke C, Bachmann A, Descazeaud A, et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol 2015;67:1099-109.

2. Hecht SL, Hedges JC. Diagnostic Work-Up of Lower Urinary Tract Symptoms. *Urol Clin North Am* 2016;43:299-309.
3. Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. *Urol Clin North Am* 2016;43:289-97.
4. Bosch JL, Bohnen AM, Groeneveld FP. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study. *Eur Urol* 2004;46:753-9.
5. El-Zawahry A, Alanee S, Malan-Elzawahry A. The Use of Urodynamics Assessment Before the Surgical Treatment of BPH. *Curr Urol Rep* 2016;17:73.
6. Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. *Eur Urol* 2013;64:118-40.
7. Kuang M, Vu A, Athreya S. A Systematic Review of Prostatic Artery Embolization in the Treatment of Symptomatic Benign Prostatic Hyperplasia. *Cardiovasc Intervent Radiol* 2017;40:655-63.
8. Porter T, Stoddart G, Hinchliffe A. The role of the plain X-ray in the assessment of prostatic symptoms. *Br J Urol* 1998;81:257-8.
9. Stacul F, Rossi A, Cova MA. CT urography: the end of IVU? *Radiol Med* 2008;113:658-69.
10. Little MA, Stafford Johnson DB, O'Callaghan JP, Walshe JJ. The diagnostic yield of intravenous urography. *Nephrol Dial Transplant* 2000;15:200-4.
11. Wasserman NF, Lapointe S, Eckmann DR, Rosel PR. Assessment of prostatism: role of intravenous urography. *Radiology* 1987;165:831-5.
12. O'Connor OJ, Fitzgerald E, Maher MM. Imaging of hematuria. *AJR Am J Roentgenol* 2010;195:W263-7.
13. Ahmad S, Manecksha RP, Cullen IM, et al. Estimation of clinically significant prostate volumes by digital rectal examination: a comparative prospective study. *Can J Urol* 2011;18:6025-30.
14. Stravodimos KG, Petrolekas A, Kapetanakis T, et al. TRUS versus transabdominal ultrasound as a predictor of enucleated adenoma weight in patients with BPH: a tool for standard preoperative work-up? *Int Urol Nephrol* 2009;41:767-71.
15. Yuen JS, Ngiap JT, Cheng CW, Foo KT. Effects of bladder volume on transabdominal ultrasound measurements of intravesical prostatic protrusion and volume. *Int J Urol* 2002;9:225-9.
16. Tatar IG, Ergun O, Celtikci P, Birgi E, Hekimoglu B. Value of prostate gland volume measurement by transrectal US in prediction of the severity of lower urinary tract symptoms. *Med Ultrason* 2014;16:315-8.
17. Danish Qaseem SM, Ghonge NP, Aggarwal B, Singhal S. Prospective evaluation of prostate with transrectal spectral Doppler with biopsy correlation: a clinicopathologic study. *Br J Radiol* 2016;89:20150830.
18. Shinbo H, Kurita Y. Application of ultrasonography and the resistive index for evaluating bladder outlet obstruction in patients with benign prostatic hyperplasia. *Curr Urol Rep* 2011;12:255-60.
19. Foo KT. Decision making in the management of benign prostatic enlargement and the role of transabdominal ultrasound. *Int J Urol* 2010;17:974-9.
20. Kuo TL, Teo JS, Foo KT. The role of intravesical prostatic protrusion (IPP) in the evaluation and treatment of bladder outlet obstruction (BOO). *Neurourol Urodyn* 2016;35:535-7.
21. Nose H, Foo KT, Lim KB, Yokoyama T, Ozawa H, Kumon H. Accuracy of two noninvasive methods of diagnosing bladder outlet obstruction using ultrasonography: intravesical prostatic protrusion and velocity-flow video urodynamics. *Urology* 2005;65:493-7.
22. Chiang P, Chuang YC, Huang CC, Chiang CP. Pilot study of transperineal injection of dehydrated ethanol in the treatment of prostatic obstruction. *Urology* 2003;61:797-801.
23. Tan YH, Foo KT. Intravesical prostatic protrusion predicts the outcome of a trial without catheter following acute urine retention. *J Urol* 2003;170:2339-41.
24. Wang D, Huang H, Law YM, Foo KT. Relationships between Prostatic Volume and Intravesical Prostatic Protrusion on Transabdominal Ultrasound and Benign Prostatic Obstruction in Patients with Lower Urinary Tract Symptoms. *Ann Acad Med Singapore* 2015;44:60-5.
25. Ahmed AF. Sonographic Parameters Predicting the Outcome of Patients With Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treated With Alpha1-Adrenoreceptor Antagonist. *Urology* 2016;88:143-8.
26. Shin SH, Kim JW, Oh MM, Moon du G. Defining the degree of intravesical prostatic protrusion in association with bladder outlet obstruction. *Korean J Urol* 2013;54:369-72.

27. Suzuki T, Otsuka A, Ozono S. Combination of intravesical prostatic protrusion and resistive index is useful to predict bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. *Int J Urol* 2016;23:929-33.
28. Arnolds M, Oelke M. Positioning invasive versus noninvasive urodynamics in the assessment of bladder outlet obstruction. *Curr Opin Urol* 2009;19:55-62.
29. Ho CC, Ngoo KS, Hamzaini AH, Rizal AM, Zulkifli MZ. Urinary bladder characteristics via ultrasound as predictors of acute urinary retention in men with benign prostatic hyperplasia. *Clin Ter* 2014;165:75-81.
30. Miyashita H, Kojima M, Miki T. Ultrasonic measurement of bladder weight as a possible predictor of acute urinary retention in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. *Ultrasound Med Biol* 2002;28:985-90.
31. Grossfeld GD, Coakley FV. Benign prostatic hyperplasia: clinical overview and value of diagnostic imaging. *Radiol Clin North Am* 2000;38:31-47.
32. Kang TW, Song JM, Kim KJ, et al. Clinical application of computed tomography on prostate volume estimation in patients with lower urinary tract symptoms. *Urol J* 2014;11:1980-3.
33. Coakley FV, Oto A, Alexander LF, et al. ACR Appropriateness Criteria((R)) Prostate Cancer-Pretreatment Detection, Surveillance, and Staging. *J Am Coll Radiol* 2017;14:S245-S57.
34. Guneyli S, Ward E, Thomas S, et al. Magnetic resonance imaging of benign prostatic hyperplasia. *Diagn Interv Radiol* 2016;22:215-9.
35. Turkbey B, Huang R, Vourganti S, et al. Age-related changes in prostate zonal volumes as measured by high-resolution magnetic resonance imaging (MRI): a cross-sectional study in over 500 patients. *BJU Int* 2012;110:1642-7.
36. Guneyli S, Ward E, Peng Y, et al. MRI evaluation of benign prostatic hyperplasia: Correlation with international prostate symptom score. *J Magn Reson Imaging* 2017;45:917-25.
37. Wasserman NF, Spilseth B, Golzarian J, Metzger GJ. Use of MRI for Lobar Classification of Benign Prostatic Hyperplasia: Potential Phenotypic Biomarkers for Research on Treatment Strategies. *AJR Am J Roentgenol* 2015;205:564-71.
38. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. *N Engl J Med* 2018;378:1767-77.
39. American College of Radiology. ACR Appropriateness Criteria® Radiation Dose Assessment Introduction. Available at: <https://www.acr.org/-/media/ACR/Files/Appropriateness-Criteria/RadiationDoseAssessmentIntro.pdf>. Accessed March 30, 2019.

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.